These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25690084)

  • 1. Challenges in the delivery of peptide drugs: an industry perspective.
    Lewis AL; Richard J
    Ther Deliv; 2015 Feb; 6(2):149-63. PubMed ID: 25690084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smart polymers for controlled delivery of proteins and peptides: a review of patents.
    Fogueri LR; Singh S
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):40-8. PubMed ID: 19149728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiomers: potential excipients for non-invasive peptide delivery systems.
    Bernkop-Schnürch A; Krauland AH; Leitner VM; Palmberger T
    Eur J Pharm Biopharm; 2004 Sep; 58(2):253-63. PubMed ID: 15296953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel delivery systems for improving the clinical use of peptides.
    Kovalainen M; Mönkäre J; Riikonen J; Pesonen U; Vlasova M; Salonen J; Lehto VP; Järvinen K; Herzig KH
    Pharmacol Rev; 2015 Jul; 67(3):541-61. PubMed ID: 26023145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commercial challenges of protein drug delivery.
    Brown LR
    Expert Opin Drug Deliv; 2005 Jan; 2(1):29-42. PubMed ID: 16296733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems.
    Truong-Le V; Lovalenti PM; Abdul-Fattah AM
    Adv Drug Deliv Rev; 2015 Oct; 93():95-108. PubMed ID: 26277263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in oral peptide delivery: lessons learnt from the clinic and future prospects.
    Richard J
    Ther Deliv; 2017 Jul; 8(8):663-684. PubMed ID: 28730934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery.
    Shoyele SA; Slowey A
    Int J Pharm; 2006 May; 314(1):1-8. PubMed ID: 16563674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smart polymer based delivery systems for peptides and proteins.
    Al-Tahami K; Singh J
    Recent Pat Drug Deliv Formul; 2007; 1(1):65-71. PubMed ID: 19075875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term delivery of protein therapeutics.
    Vaishya R; Khurana V; Patel S; Mitra AK
    Expert Opin Drug Deliv; 2015 Mar; 12(3):415-40. PubMed ID: 25251334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in protein and peptide delivery by noninvasive routes.
    Wearley LL
    Crit Rev Ther Drug Carrier Syst; 1991; 8(4):331-94. PubMed ID: 1769066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturing techniques and excipients used during the design of biodegradable polymer-based microspheres containing therapeutic peptide/protein for parenteral controlled drug delivery.
    Tamilvanan S; Venkatesh Babu R; Kannan K; Basu SK; Sa B
    PDA J Pharm Sci Technol; 2008; 62(2):125-54. PubMed ID: 18540538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein and peptide parenteral controlled delivery.
    Pawar R; Ben-Ari A; Domb AJ
    Expert Opin Biol Ther; 2004 Aug; 4(8):1203-12. PubMed ID: 15268656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-based vehicles for therapeutic peptide delivery.
    Zhang J; Desale SS; Bronich TK
    Ther Deliv; 2015; 6(11):1279-96. PubMed ID: 26599420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional matrices for oral peptide delivery.
    Bernkop-Schnürch A; Walker G
    Crit Rev Ther Drug Carrier Syst; 2001; 18(5):459-501. PubMed ID: 11763498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niosomes in sustained and targeted drug delivery: some recent advances.
    Azeem A; Anwer MK; Talegaonkar S
    J Drug Target; 2009 Nov; 17(9):671-89. PubMed ID: 19845484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer.
    Podust VN; Sim BC; Kothari D; Henthorn L; Gu C; Wang CW; McLaughlin B; Schellenberger V
    Protein Eng Des Sel; 2013 Nov; 26(11):743-53. PubMed ID: 24133142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.
    Bak A; Leung D; Barrett SE; Forster S; Minnihan EC; Leithead AW; Cunningham J; Toussaint N; Crocker LS
    AAPS J; 2015 Jan; 17(1):144-55. PubMed ID: 25398427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable implants for the sustained release of protein and peptide drugs.
    Agarwal P; Rupenthal ID
    Drug Discov Today; 2013 Apr; 18(7-8):337-49. PubMed ID: 23410799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.